BD111 + ganciclovir + valacyclovir + prednisolone acetate

This is a **combination regimen** comprising BD111, ganciclovir, valacyclovir, and prednisolone acetate, studied as therapy for **herpes simplex virus type 1 (HSV-1) stromal keratitis**. - **BD111** is a lentivirus-like particle delivering gRNA cassettes and SpCas9 mRNA, using **CRISPR/Cas9 gene editing** to target and cleave the HSV-1 genome in corneal cells, aiming for potential viral eradication rather than simple suppression. - **Ganciclovir** is a nucleoside analogue antiviral inhibiting viral DNA polymerase, thereby blocking viral DNA synthesis. - **Valacyclovir** is a prodrug of acyclovir, an antiviral nucleoside analogue that inhibits viral DNA replication by acting as a chain terminator for viral DNA polymerase. - **Prednisolone acetate** is a synthetic glucocorticoid used to reduce corneal inflammation associated with the immune response to HSV-1 infection. This multi-drug regimen is designed to target HSV-1 via different mechanisms: direct viral genome cleavage (BD111), inhibition of viral replication (ganciclovir and valacyclovir), and immune-mediated inflammation suppression (prednisolone acetate)[1][3][5].